HF 4
The percentage of patients with a current diagnosis of heart failure due to LVD who are currently treated with an ACE inhibitor or Angiotensin Receptor Blocker, who are additionally treated with a beta-blocker licensed for heart failure, or recorded as intolerant to or having a contraindication to beta-blockers.
| Indicator | Year | Numerator | Denominator | Ratio | Centile |
|---|---|---|---|---|---|
| HF 4 | 2011 | 343 | 411 | 83.5% | |
| HF 4 | 2012 | 366 | 424 | 86.3% | |
| HF 4 | 2013 | 387 | 436 | 88.8% | |
| HF004 | 2014 | 154 | 166 | 92.8% | |
| HF004 | 2015 | 235 | 241 | 97.5% | |
| HF004 | 2016 | 276 | 287 | 96.2% | |
| HF004 | 2017 | 316 | 324 | 97.5% | |
| HF004 | 2018 | 423 | 436 | 97.0% | |
| HF004 | 2019 | 452 | 470 | 96.2% |
